Company intelligence / Profile preview
Medigene AG
Martinsried, Bavaria, Germanymedigene.com ↗
- Ownership
- Private
- Employees
- ~65
- Development stage
- Phase 1
01
Overview
Medigene AG develops proprietary T cell receptor-guided immunotherapies targeting solid tumors. Its lead autologous third-generation TCR-T candidate, MDG1015 targeting NY‑ESO‑1, received FDA IND clearance in Q3/2024. The company’s pipeline includes both wholly owned and partnered assets leveraging its End-to-End Platform for generating highly specific/sensitive/safe (“3S”) TCRs. Recent strategic shifts prioritize licensing over self-funded clinical trials due to capital market constraints. Partnerships with BioNTech, Regeneron, WuXi Biologics validate the technology platform. A new off-the-shelf program with WuXi targets KRAS G12V; proof-of-principle data expected by end of 2025 may trigger further licensing deals.[1][2][3][4]
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- TCR-T cell therapies (autologous and off-the-shelf)TCR-T cell engagers (TCR-TCEs)TCR-natural killer cell therapies[1][2][4]
- Industry
- Biotech
02
Drug pipeline
25 assets24 more assets in the full pipeline.
03
Partnerships
BioNTech (comprehensive R&D partnership)[3][4]Regeneron [4]WuXi Biologics [joint development of MDG3010; off-the-shelf program targeting KRAS G12V neoantigen].[4]– Historical partnerships include bluebird bio,[3] Roivant/Sinovant/Cytovant Sciences,[3] Almirall,[4] Candid Therapeutics,[4], GlaxoSmithKline/GSK.[4]
Beyond the preview
Go deeper on Medigene AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medigene AG.